JOHNSON & JOHNSON — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Johnson & Johnson closed its $1.0B cash acquisition of Firefly Bio, Inc. (degrader antibody conjugate platform for KRAS-driven cancers) on 29 July 2026, to be expensed as ~$1B in-process R&D charge in Q3 2026. Simultaneously, J&J announced a collaboration with Sail Biomedicines with $785M initial payments ($465M equity investment + $140M contingent development milestones) plus an exclusive $2.58B acquisition option; Sail develops in vivo CAR-T therapies for immune-mediated diseases. Combined expected EPS dilution: ~$0.46 in 2026 and ~$0.08–$1.28 in 2027 (depending on Sail option exercise).
Why this rating
~$3.6B total commitment (~0.98% of $367B market cap) is material in absolute terms but routine for a mega-cap pharma; standard strategic R&D/pipeline investments; no going-concern, guidance collapse, or forced leadership change.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.